Physics-based generative AI platform (MAUD 1.0) for designing peptide macrocycle drugs de novo against challenging protein-protein interface targets.
Menten AI has developed MAUD 1.0, a proprietary generative AI platform that designs peptide macrocycles de novo for complex drug targets including challenging protein-protein interfaces. The platform combines generative AI with physics-based models and quantum simulations to design and optimize drug-like peptides, achieving nanomolar-level potency, cell permeability, and over 90% hit rates. It is validated across the preclinical discovery pipeline and is trusted by top-10 pharmaceutical partners and backed by leading VCs. Menten AI is a product of Menten AI.